ARTICLE | Company News
Prolong Pharmaceuticals Inc., Valentis deal
February 17, 2003 8:00 AM UTC
VLTSD licensed its OptiPEG PEGylation technology to biogenerics company Prolong to develop and market PEGylated protein therapeutics. VLTSD will receive an upfront cash payment, and is eligible for mi...